(Translated by https://www.hiragana.jp/)
别孕烷醇酮 - 维基百科,自由的百科全书 とべ转到内容ないよう

别孕烷醇酮

维基百科ひゃっか自由じゆうてき百科ひゃっかぜん
别孕烷醇酮
Skeletal formula of allopregnanolone
Ball-and-stick model of the allopregnanolone molecule
臨床りんしょう資料しりょう
商品しょうひんめいえいDrug nomenclatureZulresso
其他名稱めいしょうALLO; Allo; ALLOP; AlloP; Brexanolone; SAGE-547; SGE-102; 5αあるふぁ-Pregnan-3αあるふぁ-ol-20-one; 3αあるふぁ-Hydroxy-5αあるふぁ-pregnan-20-one; 3αあるふぁ,5αあるふぁ-Tetrahydroprogesterone; 3αあるふぁ,5αあるふぁ-THP
给药みちIntravenous infusion[1]
藥物やくぶつ類別るいべつえいDrug classNeurosteroids; Antidepressants
法律ほうりつ規範きはん狀態じょうたい
法律ほうりつ規範きはん
藥物やくぶつ動力どうりょくがくかずよりどころ
血漿けっしょう蛋白たんぱく結合けつごうりつ>99%[1]
药物だいNon-CYP450 (keto-reduction via AKRs, glucuronidation via UGTs, sulfation via SULTs)[1]
生物せいぶつはんおとろえ9 hours[1]
排泄はいせつみちFeces: 47%[1]
Urine: 42%[1]
识别しんいき
  • 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
    OR
    1-[(1S,2S,5R,7S,10R,11S,14S,15S)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.02,7.011,15]heptadec-14-yl]ethanone
CASごう516-54-1
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox DashboardえいCompTox Chemicals Dashboard (EPA)
化学かがくしんいき
化学かがくしきC21H34O2
尔质りょう318.501 g/mol
3D模型もけいJSmolえいJSmol
  • CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@H](C4)O)C)C
  • InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1
  • Key:AURFZBICLPNKBZ-SYBPFIFISA-N

别孕烷醇酮英語えいごallopregnanoloneALLO,也名为3αあるふぁ,5αあるふぁ-孕烷あつし酮)一种作用于大脑的神经甾体[2][3]可用かよう于治疗产后そもそもいくしょう[3][4][5]

参考さんこう文献ぶんけん

[编辑]
  1. ^ 1.0 1.1 1.2 1.3 1.4 1.5 そん副本ふくほん (PDF). [2019-05-26]. (原始げんし内容ないようそん (PDF)于2020-11-12). 
  2. ^ Reddy DS. Neurosteroids: endogenous role in the human brain and therapeutic potentials. Progress in Brain Research 186. 2010: 113–37. ISBN 9780444536303. PMC 3139029可免费查阅. PMID 21094889. doi:10.1016/B978-0-444-53630-3.00008-7.  |journal=ゆるがせりゃく (帮助)
  3. ^ 3.0 3.1 Commissioner, Office of the. Press Announcements - FDA approves first treatment for post-partum depression. www.fda.gov. [21 March 2019]. (原始げんし内容ないようそん于2019-04-22) えい语). 
  4. ^ Frieder A, Fersh M, Hainline R, Deligiannidis KM. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development. CNS Drugs. March 2019, 33 (3): 265–282. PMID 30790145. doi:10.1007/s40263-019-00605-7. 
  5. ^ Wilkinson ST, Sanacora G. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discov. Today. February 2019, 24 (2): 606–615. PMID 30447328. doi:10.1016/j.drudis.2018.11.007.